Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker LLY · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3C… NCT07935317 · Breast Neoplasms Abemaciclib, Tersolisib | LLY Eli Lilly and Company | Phase 2 | Not yet recruiting | 120 | Dec 2027 | Registry ↗ |
| Nov 13, 2026 | A Study Assessing Eloralintide (LY3841136) in Healthy Participants NCT07935304 · Healthy Eloralintide, Eloralintide | LLY Eli Lilly and Company | Phase 1 | Not yet recruiting | 90 | Apr 2027 | Registry ↗ |
| Nov 13, 2026 | A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS). NCT07883590 · Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme Syst… LY3873862, CYP450 Drug Cocktail | LLY Eli Lilly and Company | Phase 1 | Not yet recruiting | 32 | Nov 2027 | Registry ↗ |
| Nov 13, 2026 | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Se… NCT06297603 · Type 2 Diabetes Retatrutide, Placebo | LLY Eli Lilly and Company | Phase 3 | Active, not recruiting | 320 | Oct 26, 2026 | Registry ↗ |
| Nov 12, 2026 | A Study of LY4175408 in Participants With Advanced Cancer NCT07046923 · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma LY4175408, Pembrolizumab | LLY Eli Lilly and Company | Phase 1 | Active, not recruiting was recruiting | 240 | Jul 2030 | Registry ↗ |
| Nov 12, 2026 | A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis NCT06220669 · Multiple Sclerosis LY3541860, Placebo | LLY Eli Lilly and Company | Phase 2 | Terminated | 65 | Oct 18, 2025 | Registry ↗ |
| Nov 12, 2026 | A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesi… NCT05556512 · Obesity, Overweight Tirzepatide, Placebo | LLY Eli Lilly and Company | Phase 3 | Active, not recruiting | 15,374 | Oct 2027 | Registry ↗ |
| Nov 12, 2026 | A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type… NCT05433584 · Type 2 Diabetes Tirzepatide, Antihyperglycemic medication | LLY Eli Lilly and Company | Phase 4 | Active, not recruiting | 794 | Oct 21, 2025 | Registry ↗ |
| Nov 10, 2026 | A Study of LY4336619 in Adult Participants With Advanced Solid Tumors NCT07928258 · Endometrial Neoplasms, Ovarian Neoplasms LY4336619, Sofetabart Mipitecan (Sofe-M) | LLY Eli Lilly and Company | Phase 1 | Not yet recruiting | 370 | Mar 2032 | Registry ↗ |
| Nov 10, 2026 | A Study of Brenipatide in Participants With Major Depressive Disorder NCT07928245 · Major Depressive Disorder Brenipatide, Placebo | LLY Eli Lilly and Company | Phase 2 | Not yet recruiting | 330 | May 2028 | Registry ↗ |
| Nov 10, 2026 | A Study of LY3981314 in Participants With Autoimmune Hepatitis NCT07928219 · Hepatitis Autoimmune Disease, Hepatitis LY3981314 | LLY Eli Lilly and Company | Phase 1 | Not yet recruiting | 12 | Jun 2028 | Registry ↗ |
| Nov 10, 2026 | A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight NCT07232719 · Obesity, Overweight Retatrutide, Placebo | LLY Eli Lilly and Company | Phase 3 | Active, not recruiting | 250 | Jun 2027 | Registry ↗ |
| Nov 10, 2026 | A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors NCT06561685 · Metastatic Solid Tumor, Advanced Solid Tumor LY4050784, Pembrolizumab | LLY Eli Lilly and Company | Phase 1 | Active, not recruiting was recruiting | 340 | Oct 2027 | Registry ↗ |
| Nov 9, 2026 | A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity NCT07232732 · Healthy, Obesity LY3549492 | LLY Eli Lilly and Company | Phase 1 | Completed | 120 | Jul 17, 2026 | Registry ↗ |
| Nov 9, 2026 | A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and… NCT05936151 · Overweight or Obesity, CKD Retatrutide, Placebo | LLY Eli Lilly and Company | Phase 2 | Completed | 146 | Oct 1, 2025 | Registry ↗ |
| Nov 6, 2026 | A Study of Bimagrumab in Participants With HFpEF NCT07920887 · Heart Failure, Diastolic, Diastolic Heart Failure Bimagrumab, Placebo | LLY Eli Lilly and Company | Phase 2 | Not yet recruiting | 540 | Jul 2029 | Registry ↗ |
| Nov 6, 2026 | A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer NCT07258836 · Neoplasms, Healthy LY4214835 | LLY Eli Lilly and Company | Phase 1 | Recruiting | 41 | Dec 2027 | Registry ↗ |
| Nov 5, 2026 | A Study of Imlunestrant (LY3484356) in Healthy Female Participants NCT07918859 · Healthy Imlunestrant (Test), Imlunestrant (Reference) | LLY Eli Lilly and Company | Phase 1 | Not yet recruiting | 343 | Aug 2027 | Registry ↗ |
| Nov 5, 2026 | A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related C… NCT07794579 · Overweight, Prediabetic State Orforglipron, Placebo | LLY Eli Lilly and Company | Phase 3 | Recruiting | 2,001 | Aug 2029 | Registry ↗ |
| Nov 5, 2026 | A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Partici… NCT07787169 · Alzheimer Disease, Amyloid LY4405094, LY4405094 | LLY Eli Lilly and Company | Phase 1 | Recruiting | 179 | Jul 2028 | Registry ↗ |
| Nov 5, 2026 | A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructiv… NCT07759245 · Pulmonary Disease, Chronic Obstructive Brenipatide, Placebo | LLY Eli Lilly and Company | Phase 2 | Recruiting | 606 | May 2028 | Registry ↗ |
| Nov 5, 2026 | A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2… NCT07668336 · Diabetes Mellitus, Type 2 Orforglipron, Dulaglutide | LLY Eli Lilly and Company | Phase 3 | Recruiting | 170 | Mar 2030 | Registry ↗ |
| Nov 5, 2026 | A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-… NCT07545772 · Irritable Bowel Syndrome, Constipation LY3537031, Placebo | LLY Eli Lilly and Company | Phase 2 | Recruiting | 342 | Jul 2027 | Registry ↗ |
| Nov 5, 2026 | A Study of LY4515100 in Healthy Participants NCT07339722 · Healthy LY4515100 via SAD, LY4515100 via MAD | LLY Eli Lilly and Company | Phase 1 | Recruiting | 209 | Mar 2027 | Registry ↗ |
| Nov 5, 2026 | A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moder… NCT07219173 · Asthma Brenipatide, Brenipatide | LLY Eli Lilly and Company | Phase 2 | Recruiting | 531 | Apr 2028 | Registry ↗ |
| Nov 5, 2026 | A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis NCT07100119 · ALS (Amyotrophic Lateral Sclerosis) LY4256984, Placebo | LLY Eli Lilly and Company | Phase 1 | Recruiting | 36 | Aug 2027 | Registry ↗ |
| Nov 5, 2026 | A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participa… NCT05986292 · Osteoarthritis, Knee, Diabetic Neuropathic Pain LY3016859 ISA, LY3556050 ISA | LLY Eli Lilly and Company | Phase 2 | Recruiting | 10,000 | Apr 2027 | Registry ↗ |
| Nov 4, 2026 | A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy NCT07915245 · Obesity, Overweight LY4247147, LY4247147 | LLY Eli Lilly and Company | Phase 1 | Not yet recruiting | 108 | Oct 2028 | Registry ↗ |
| Nov 4, 2026 | A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a) NCT07914738 · Lipoprotein(a) LY3819469 | LLY Eli Lilly and Company | Phase 1 | Not yet recruiting | 66 | Mar 2027 | Registry ↗ |
| Nov 4, 2026 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes NCT07881458 · Obesity, Overweight eloralintide and tirzepatide, Tirzepatide | LLY Eli Lilly and Company | Phase 3 | Recruiting was not yet recruiting | 1,000 | Oct 2029 | Registry ↗ |
| Nov 4, 2026 | Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Ped… NCT07817875 · Obesity Tirzepatide, Placebo | LLY Eli Lilly and Company | Phase 3 | Recruiting | 150 | Dec 2029 | Registry ↗ |
| Nov 4, 2026 | A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain NCT07641517 · Osteoarthritis, Knee, Chronic Pain LY4065967, Placebo | LLY Eli Lilly and Company | Phase 2 | Recruiting | 150 | Apr 2027 | Registry ↗ |
| Nov 4, 2026 | A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back P… NCT07641504 · Chronic Pain, Low Back Pain LY4065967, Placebo | LLY Eli Lilly and Company | Phase 2 | Recruiting | 150 | Apr 2027 | Registry ↗ |
| Nov 4, 2026 | A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a)… NCT07613294 · Atherosclerosis, Cardiovascular Diseases Lepodisiran, Placebo | LLY Eli Lilly and Company | Phase 3 | Recruiting | 252 | Dec 2029 | Registry ↗ |
| Nov 4, 2026 | A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizuma… NCT07612267 · Lactation, Inflammatory Bowel Disease Mirikizumab | LLY Eli Lilly and Company | Phase 4 | Recruiting | 14 | Sep 2028 | Registry ↗ |
| Nov 4, 2026 | A Study of LY3439539 in Participants With Alzheimer's Disease NCT07598370 · Alzheimer Disease LY3439539 | LLY Eli Lilly and Company | Phase 1 | Recruiting | 30 | Aug 2027 | Registry ↗ |
| Nov 4, 2026 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) NCT07589595 · Cognitive Dysfunction, Lewy Body Disease Donanemab, Placebo | LLY Eli Lilly and Company | Phase 2 | Recruiting | 350 | Aug 2028 | Registry ↗ |
| Nov 4, 2026 | A Study of LY3971297 in Participants With Heart Failure NCT07547540 · Heart Failure, Heart Failure, Diastolic LY3971297, LY3971297 | LLY Eli Lilly and Company | Phase 1 | Recruiting | 90 | Nov 2027 | Registry ↗ |
| Nov 4, 2026 | A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) NCT07545759 · Irritable Bowel Syndrome, Diarrhea LY3537031, Placebo | LLY Eli Lilly and Company | Phase 2 | Recruiting | 531 | Sep 2027 | Registry ↗ |
| Nov 4, 2026 | A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo NCT07533019 · Vitiligo, Non-Segmental Vitiligo (NSV) LY4005130, Placebo | LLY Eli Lilly and Company | Phase 2 | Recruiting | 66 | May 2027 | Registry ↗ |
| Nov 4, 2026 | A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) NCT07533006 · Alopecia Areata LY4005130, Placebo | LLY Eli Lilly and Company | Phase 2 | Recruiting | 65 | Jun 2027 | Registry ↗ |
| Nov 4, 2026 | Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy NCT07503613 · Vestibular Schwannoma | LLY Eli Lilly and Company | — | Enrolling by invitation | 100 | Apr 2040 | Registry ↗ |
| Nov 4, 2026 | A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults W… NCT07483099 · Crohn Disease LY4395089, Mirikizumab - Intravenous (IV) | LLY Eli Lilly and Company | Phase 2 | Recruiting | 60 | Jun 2027 | Registry ↗ |
| Nov 4, 2026 | A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Di… NCT07483073 · Colitis, Ulcerative, Crohn Disease Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous… | LLY Eli Lilly and Company | Phase 2 | Recruiting | 60 | Jun 2027 | Registry ↗ |
| Nov 4, 2026 | A Study of Brenipatide in Participants With Opioid Use Disorder NCT07420283 · Opioid Use Disorder Brenipatide, Placebo | LLY Eli Lilly and Company | Phase 2 | Recruiting | 465 | Mar 2028 | Registry ↗ |
| Nov 4, 2026 | LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis NCT07415044 · Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate LY4268989, Placebo | LLY Eli Lilly and Company | Phase 2 | Recruiting | 1,431 | Jun 2030 | Registry ↗ |
| Nov 4, 2026 | A Study of Brenipatide in Adult Participants With Major Depressive Disorder NCT07412756 · Depressive Disorder, Major Brenipatide, Placebo | LLY Eli Lilly and Company | Phase 3 | Recruiting | 1,000 | Feb 2028 | Registry ↗ |
| Nov 4, 2026 | A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a… NCT07392190 · Overweight, Obesity Eloralintide, Placebo | LLY Eli Lilly and Company | Phase 3 | Recruiting | 900 | Jun 2028 | Registry ↗ |
| Nov 4, 2026 | A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Ove… NCT07369011 · Sleep Apnea, Obstructive, Obesity Eloralintide, Placebo | LLY Eli Lilly and Company | Phase 3 | Recruiting | 800 | Mar 2028 | Registry ↗ |
| Nov 4, 2026 | Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and O… NCT07353931 · Osteoarthritis, Overweight or Obesity Eloralintide, Placebo | LLY Eli Lilly and Company | Phase 3 | Recruiting | 900 | Mar 2028 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:18 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances